Molecular Characterization and Pathogenicity of a Novel Recombinant NADC30-Like PRRSV Strain Isolated From Piglets Inducing Intestinal Inflammation, and Construction of Its Infectious Clone

从仔猪中分离出一种新型重组NADC30样PRRSV毒株,该毒株可诱发肠道炎症,并对其进行分子特征分析和致病性研究,以及构建其感染性克隆。

阅读:4
作者:Yafang Lin,Yan Ouyang,Jiayang Zheng,Changguang Xiao,Yang Yang,Qianming Zhao,Yan Zhang,Zongjie Li,Ke Liu,Beibei Li,Donghua Shao,Yafeng Qiu,Zhiyong Ma,Jianchao Wei

Abstract

Porcine reproductive and respiratory syndrome virus (PRRSV) causes major economic losses in swine production worldwide, characterized by reproductive failure and respiratory disease. In China, the cocirculation of diverse strains drives ongoing viral evolution and the emergence of novel recombinants, posing serious challenges for disease control. Here, we report the isolation and characterization of a novel PRRSV strain (JS-YZ/2023) from a PRRS-suspected pig farm. Genomic analysis revealed a unique recombinant pattern between NADC30-like and HP-PRRSV lineages, distinct from previously reported recombinants. Experimental infection in piglets demonstrated significant pathogenicity, with persistent fever, severe anorexia, progressive weight loss, and pathological lesions including interstitial pneumonia with lymphocyte infiltration and marked disruption of intestinal villi. Notably, JS-YZ/2023 exhibited strong intestinal tropism, inducing a local cytokine storm in the small intestine and showing PRRSV-N protein antigen accumulation in crypt epithelial cells, as detected by immunohistochemistry. In addition, we successfully constructed a full-length infectious cDNA clone of JS-YZ/2023 incorporating a green fluorescent protein (GFP) reporter gene (rGFP-JS-YZ/2023). This engineered virus provides a valuable tool for investigating the pathogenic mechanisms of NADC30-like recombinants and facilitating vaccine development.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。